

Rumphellclovane B, a Novel Clovane Analogue from the Gorgonian Coral *Rumphella antipathies*

Hsu-Ming Chung,^{1,2} Tsong-Long Hwang,³ Yung-Husan Chen,² Jui-Hsin Su,² Mei-Chin Lu,^{2,4} Jih-Jung Chen,⁵ Jan-Jung Li,² Lee-Shing Fang,⁶ Wei-Hsien Wang,^{*1,2,7} and Ping-Jyun Sung^{*1,2,4,7,8}

¹Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804, Taiwan

²National Museum of Marine Biology and Aquarium, Pingtung 944, Taiwan

³Graduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan

⁴Graduate Institute of Marine Biotechnology, National Dong Hwa University, Pingtung 944, Taiwan

⁵Department of Pharmacy, Tajen University, Pingtung 907, Taiwan

⁶Department of Sport, Health, and Leisure, Cheng Shiu University, Kaohsiung 833, Taiwan

⁷Asia-Pacific Ocean Research Center, National Sun Yat-sen University, Kaohsiung 804, Taiwan

⁸Department of Life Science and the Institute of Biotechnology, National Dong Hwa University, Hualien 974, Taiwan

Received September 7, 2010; E-mail: pjsung@nmmmba.gov.tw, whw@mail.nsysu.edu.tw

A novel clovane-type sesquiterpenoid derivative, rumphellclovane B (**1**), which possesses an unprecedented δ -lactone moiety, and a new natural clovane, 9 α -hydroxyclovan-2-one (**2**), were isolated from the gorgonian coral *Rumphella antipathies*. The structures of clovanes **1** and **2** were elucidated by interpretations of spectral data. A plausible biosynthetic pathway between these two compounds was proposed. Compound **1** displayed inhibitory effects on superoxide anion generation by human neutrophils.

Previous chemical investigations on gorgonian coral *Rumphella antipathies* have yielded a series of interesting caryophyllane- and clovane-related sesquiterpenoid derivatives, including kobusone,¹ isokobusone,² rumphellatins A–C,^{3–5} rumphellolides A–I,^{6–9} and rumphellclovane A.¹⁰ In our continuing studies on *R. antipathies*, a novel clovane-related sesquiterpenoid derivative, rumphellclovane B (**1**), along with a new natural clovane, 9 α -hydroxyclovan-2-one (**2**) (Chart 1),^{11–13} were isolated. In this paper, we describe the isolation, structure characterization, plausible biosynthetic pathway, and bioactivity of sesquiterpenoids **1** and **2**.

Results and Discussion

Rumphellclovane B (**1**) was isolated as a colorless oil that gave a pseudomolecular ion $[M + Na]^+$ at m/z 275.1625 in the HR-ESI-MS, indicating the molecular formula $C_{15}H_{24}O_3$ (calcd for $C_{15}H_{24}O_3 + Na$, 275.1623) and implying four degrees of unsaturation. IR absorptions were observed at 3459 and 1730 cm^{-1} , suggesting the presence of hydroxy and δ -lactone groups in **1**. The ^{13}C NMR and DEPT spectra of **1** (Table 1) showed that this compound has 15 carbons, including three methyls, six sp^3 methylenes, two sp^3 methines, and four quaternary carbons. From the ^{13}C NMR data, a degree of unsaturation was accounted for (δ_C 172.0, s, an ester carbonyl) and **1** must be a tricyclic compound.

From the 1H – 1H COSY experiment of **1** (Figure 1), it was possible to establish the spin systems that map out the proton sequences from H-5/H₂-6/H₂-7 and H-9/H₂-10/H₂-11, which




Chart 1.




were assembled with the assistance of an HMBC experiment. The HMBC correlations between protons and quaternary carbons of **1**, such as H-6a, H₂-10, H₂-11/C-1; H₂-3/C-2; H₂-3, H-5, H-6a/C-4; H₂-7/C-8, permitted elucidation of the main carbon skeleton. The tertiary methyl at C-8 was confirmed by the HMBC correlations between H₃-15/C-7, -8, -9. Moreover, the two tertiary methyls at C-4 were elucidated by the HMBC correlations between H₃-13/C-3, -4, -5, -14 and H₃-14/C-3, -4, -5, -13. The C-12 methylene bridge between C-1 and C-8 was linked by the HMBC correlations between H₂-7, H₂-11, H₃-15/C-12; and H₂-12/C-1, -5, -7, -8, -9, -15 (Figure 1). Based on the consideration of molecular formula, an additional oxygen atom had to be placed between C-1 and C-2 to form a δ -lactone moiety.

The relative configuration of **1** was established from the interactions observed in a NOESY experiment (Figure 2). Because of the β -orientation of H-5, and the correlations of this

Table 1. ^1H and ^{13}C NMR Data for Clovanes **1** and **2**

Position	1		2	
	$\delta_{\text{H}}^{\text{a)}$	$\delta_{\text{C}}^{\text{b)}$	$\delta_{\text{H}}^{\text{a)}$	$\delta_{\text{C}}^{\text{b)}$
1		83.2 (s) ^{d)}		49.4 (s)
2		172.0 (s)		221.3 (s)
3a/b	2.33 d (16.0) ^{c)} , 2.24 d (16.0)	44.4 (t)	2.27 d (16.0), 2.13 d (16.0)	24.2 (t)
4		34.0 (s)		36.3 (s)
5	1.58 m	45.7 (d)	1.70 m	48.9 (d)
6a/b	1.36 m, 1.61 m	21.0 (t)	1.46 m, 1.58 m	20.5 (t)
7a/b	1.47 m, 1.13 m	32.2 (t)	1.42 m, 1.18 m	32.8 (t)
8		36.1 (s)		33.7 (s)
9	3.32 br s	73.1 (d)	3.56 br s	73.9 (d)
10a/b	1.97 m, 1.75 m	26.6 (t)	1.98 m, 1.67 m	26.4 (t)
11a/b	1.98 m, 1.48 m	35.4 (t)	1.91 m, 1.12 m	29.7 (t)
12 α/β	1.75 d (12.4), 1.47 d (12.4)	36.3 (t)	1.53 d (12.8), 1.01 br d (12.8)	31.6 (t)
13	0.95 s	22.6 (q)	0.97 s	24.2 (q)
14	1.08 s	29.7 (q)	1.05 s	30.6 (q)
15	1.04 s	27.8 (q)	0.96 s	28.1 (q)

a) Spectra measured at 400 MHz in CDCl_3 at 25 °C. b) Spectra measured at 100 MHz in CDCl_3 at 25 °C. c) J values (in hertz) in parentheses. d) Attached protons were deduced by DEPT and HMQC experiments.

**Figure 1.** The ^1H - ^1H COSY and selective key HMBC correlations of **1**.**Figure 2.** Selective NOESY correlations of **1**.**Scheme 1.** Plausible biogenetic relationships for compounds **1** and **2**.

proton shows with H_3 -14 but not with H_3 -13 one can surmise that H-5 and H_3 -14 are located on the same face. One proton of C-12 methylene (δ_{H} 1.47) was found to exhibit a correlation with H_3 -13 and assigned as H-12 β and the other was assigned as H-12 α (δ_{H} 1.75). H_3 -15 showed correlations with H-12 α/β , confirming the α -orientation for this tertiary methyl. Furthermore, H-9 showed correlations with H_2 -10 and H_3 -15, but not with H-12 α . By molecular modeling analysis, H-9 was found to be reasonably close to H_2 -10 and H_3 -15 and can therefore be placed on the β face in **1**. Based on the above findings, the structure of **1** was elucidated and the chiral centers for **1** were assigned as 1 S^* , 5 S^* , 8 R^* , and 9 R^* .

Our present study has also led to the isolation of a new natural clovane **2** and this metabolite has the molecular formula $\text{C}_{15}\text{H}_{24}\text{O}_2$ as determined by HR-ESI-MS (m/z 259.1675, calcd for $\text{C}_{15}\text{H}_{24}\text{O}_2 + \text{Na}$, 259.1674), with four degrees of unsaturation. Its IR spectrum exhibits broad OH stretch at 3482 cm^{-1} and ketone carbonyl at 1729 cm^{-1} . It was found that the NMR data of **2** (Table 1) are similar with those of **1**, except that the signals corresponding to the δ -lactone group in **1** are replaced

by a ketone group in **2**. The correlations from a NOESY experiment of **2** also showed that the relative stereochemistry of **2** is similar to those of **1** and the relative configurations of chiral centers of **2** were established as 1 S^* , 5 S^* , 8 R^* , and 9 R^* . It was found that clovane **2** had been obtained previously by chemical methods and named as 9 α -hydroxyclovan-2-one (**2**).^{11–13} To the best of our knowledge, clovane **2** has not been isolated previously from natural sources. The NMR and mass data for this compound were also reported for the first time.

A plausible biosynthetic pathway for **1** from **2** was proposed as illustrated in Scheme 1. Clovane **2** was further lactonized to **1** by Baeyer–Villiger oxidation. To the best of our knowledge, clovane-type derivative like **1** containing a δ -lactone moiety has not been found previously.

In biological activity experiments, the clovanes **1** and **2** displayed 44.2 and 4.3% inhibitory effects on superoxide anion generation by human neutrophils at $10\text{ }\mu\text{g mL}^{-1}$, respectively.

Experimental

General Experimental Procedures. Optical rotation

values were measured with a JASCO P-1010 digital polarimeter. Infrared spectra were obtained on a VARIAN DIGILAB FTS 1000 FT-IR spectrophotometer. NMR spectra were recorded on a VARIAN MERCURY PLUS 400 FT-NMR at 400 MHz for ^1H and 100 MHz for ^{13}C , in CDCl_3 . Proton chemical shifts were referenced to the residual CHCl_3 signal (δ_{H} 7.26). ^{13}C NMR spectra were referenced to the center peak of CDCl_3 at δ_{C} 77.1. ESI-MS and HR-ESI-MS data were recorded on a BRUKER APEX II mass spectrometer. Column chromatography was performed on silica gel (230–400 mesh, MERCK, Darmstadt, Germany). TLC was carried out on precoated Kieselgel 60 F_{254} (0.25 mm, MERCK) and spots were visualized by spraying with 10% H_2SO_4 solution followed by heating. HPLC was performed using a system comprising a HITACHI L-7100 pump, a HITACHI photo diode array detector L-7455, and a RHEODYNE 7725 injection port. A normal phase column (Hibar 250 \times 25 mm, LiChrospher Si 60, 5 μm , MERCK) was used for HPLC.

Animal Material. Specimens of the octocoral *R. antipathies* were collected in May 2004, off the southern coast of Taiwan. A voucher specimen was deposited in the National Museum of Marine Biology and Aquarium, Taiwan.

Extraction and Isolation. Sliced bodies of *R. antipathies* (wet weight 402 g, dry weight 144 g) were extracted with a mixture of MeOH and dichloromethane (DCM) (1:1). The extract was partitioned between EtOAc and H_2O . The EtOAc layer was separated on silica gel and eluted using *n*-hexane/EtOAc (stepwise, 25:1–pure EtOAc) to yield 29 fractions. Every fraction was checked by the ^1H NMR spectra. Fraction 22 was purified by normal-phase HPLC, using the mixtures of DCM and EtOAc as a mobile phase to afford compound **1** (10:1). Fraction 18 was purified by normal-phase HPLC, using the mixtures of *n*-hexane and EtOAc as a mobile phase to afford compound **2** (4:1).

Rumphelliclovane B (1): Colorless oil (1.7 mg); $[\alpha]_{\text{D}}^{25}$ -9 (*c* 0.06, CHCl_3); IR (neat): ν_{max} 3459, 1730 cm^{-1} ; ^1H (CDCl_3 , 400 MHz) and ^{13}C (CDCl_3 , 100 MHz) NMR data, see Table 1; ESI-MS: m/z 275 $[\text{M} + \text{Na}]^+$; HR-ESI-MS: m/z 275.1625 (calcd for $\text{C}_{15}\text{H}_{24}\text{O}_3 + \text{Na}$, 275.1623).

9 α -Hydroxyclovane-2-one (2): Colorless oil (18.4 mg); $[\alpha]_{\text{D}}^{23}$ $+4$ (*c* 0.15, CHCl_3) (Ref. 12 $[\alpha]_{\text{D}}$ $+7$ (*c* 1.50, EtOH)); IR (neat): ν_{max} 3482, 1729 cm^{-1} ; ^1H (CDCl_3 , 400 MHz) and ^{13}C (CDCl_3 , 100 MHz) NMR data, see Table 1; ESI-MS: m/z 259 $[\text{M} + \text{Na}]^+$; HR-ESI-MS: m/z 259.1675 (calcd for $\text{C}_{15}\text{H}_{24}\text{O}_2 + \text{Na}$, 259.1674).

Human Neutrophil Superoxide Anion Generation. Human neutrophils were obtained by means of dextran

sedimentation and Ficoll centrifugation. Superoxide generation was carried out according to procedures described previously.^{14,15} Briefly, superoxide anion production was assayed by monitoring the superoxide dismutase-inhibitable reduction of ferricytochrome *c*.

This research work was supported by grants from the National Museum of Marine Biology and Aquarium (Grant Nos. 99200321 and 99200322); National Dong Hwa University; Asia-Pacific Ocean Research Center, National Sun Yat-sen University (Grant No. 97C031702); and the National Science and Technology Program for Biotechnology and Pharmaceuticals, National Science Council (Grant Nos. NSC 98-2323-B-291-001, 99-2323-B-291-001, and 98-2320-B-291-001-MY3), Taiwan, awarded to P.-J.S.

References

- 1 L.-F. Chuang, T.-Y. Fan, J.-J. Li, P.-J. Sung, *Biochem. Syst. Ecol.* **2007**, *35*, 470.
- 2 L.-F. Chuang, T.-Y. Fan, J.-J. Li, J. Kuo, L.-S. Fang, W.-H. Wang, P.-J. Sung, *Platax* **2007**, *4*, 61.
- 3 P.-J. Sung, L.-F. Chuang, J. Kuo, T.-Y. Fan, W.-P. Hu, *Tetrahedron Lett.* **2007**, *48*, 3987.
- 4 P.-J. Sung, L.-F. Chuang, W.-P. Hu, *Bull. Chem. Soc. Jpn.* **2007**, *80*, 2395.
- 5 P.-J. Sung, Y.-D. Su, T.-L. Hwang, L.-F. Chuang, J.-J. Chen, J.-J. Li, L.-S. Fang, W.-H. Wang, *Chem. Lett.* **2008**, *37*, 1244.
- 6 P.-J. Sung, L.-F. Chuang, J. Kuo, J.-J. Chen, T.-Y. Fan, J.-J. Li, L.-S. Fang, W.-H. Wang, *Chem. Pharm. Bull.* **2007**, *55*, 1296.
- 7 P.-J. Sung, L.-F. Chuang, T.-Y. Fan, H.-N. Chou, J. Kuo, L.-S. Fang, W.-H. Wang, *Chem. Lett.* **2007**, *36*, 1322.
- 8 T.-L. Hwang, Y.-D. Su, W.-P. Hu, L.-F. Chuang, P.-J. Sung, *Heterocycles* **2009**, *78*, 1563.
- 9 P.-J. Sung, Y.-D. Su, T.-L. Hwang, L.-F. Chuang, H.-M. Chung, J.-J. Chen, J.-J. Li, L.-S. Fang, W.-H. Wang, *Chem. Lett.* **2009**, *38*, 282.
- 10 H.-M. Chung, Y.-H. Chen, T.-L. Hwang, L.-F. Chuang, W.-H. Wang, P.-J. Sung, *Tetrahedron Lett.* **2010**, *51*, 2734.
- 11 A. Aebi, D. H. R. Barton, A. S. Lindsey, *J. Chem. Soc.* **1953**, 3124.
- 12 A. Aebi, D. H. R. Barton, A. W. Burgstahler, A. S. Lindsey, *J. Chem. Soc.* **1954**, 4659.
- 13 D. H. R. Barton, A. Nickon, *J. Chem. Soc.* **1954**, 4665.
- 14 T.-L. Hwang, G.-L. Li, Y.-H. Lan, Y.-C. Chia, P.-W. Hsieh, Y.-H. Wu, Y.-C. Wu, *Free Radical. Biol. Med.* **2009**, *46*, 520.
- 15 T.-L. Hwang, Y.-C. Su, H.-L. Chang, Y.-L. Leu, P.-J. Chung, L.-M. Kuo, Y.-J. Chang, *J. Lipid Res.* **2009**, *50*, 1395.